使用精油鼻内喷雾对常年性过敏性鼻炎患者的影响：一项前瞻性研究。,International Archives of Allergy and Immunology

当前位置： X-MOL 学术 › Int. Arch. Allergy Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

使用精油鼻内喷雾对常年性过敏性鼻炎患者的影响：一项前瞻性研究。
International Archives of Allergy and Immunology ( IF 2.8 ) Pub Date : 2020-09-22 , DOI: 10.1159/000510592
Davide Caimmi _{1,

2} , Catherine Neukirch ₃ , Renaud Louis ₄ , Olivier Malard ₅ , Gabriel Thabut ₃ , Pascal Demoly _{6,

7}

Affiliation

介绍：在过敏性鼻炎 (AR) 症状中，鼻塞尤其影响生活质量。抗组胺药和鼻内皮质类固醇是最常用的对症药物，但其疗效往往不完全。精油 (EO) 已显示出抗炎作用和治疗 AR 患者的潜力。本研究的目的是评估基于高渗 EO 的鼻喷雾剂对常年性 AR (PAR) 症状的有效性。方法：这项前瞻性、开放标签、非随机、多中心试验包括 43 名对螨虫敏感的 PAR 患者，未得到控制超过一年。所有患者均使用 Puressentiel® 呼吸减充血剂鼻喷雾剂治疗 30 天。在研究期间，他们的常规治疗保持不变。在治疗前后，每位参与者都填写了一份鼻炎问卷，即过敏性鼻炎控制测试 (ARCT)。进行鼻吸气峰流量 (NIPF)。结果： D0 和 D30 的平均ARCT分别为 16.4 和 20.5（p #x3c；0.001）；D0 和 D30 之间的平均增加为 4.1（p #x3c；0.001）。治疗 30 天后鼻炎得到控制的患者比例为 69.8%，治疗前为 14%（p#x3c; 0.001）。D0 和 D30 的平均 NIPF 分别为 86.5 L/min 和 105.1 L/min ( p #x3c; 0.001)；D0 和 D30 之间的平均增幅为 18.5 L/min。结论：基于 EO 的高渗鼻喷雾剂可能是治疗 PAR 的一种新的自然选择。当鼻部症状没有得到完全控制时，它也可以用作附加疗法。
Int Arch 过敏免疫

"点击查看英文标题和摘要"

Effect of the Use of Intranasal Spray of Essential Oils in Patients with Perennial Allergic Rhinitis: A Prospective Study.

Introduction: Among allergic rhinitis (AR) symptoms, nasal obstruction particularly affects the quality of life. Antihistamines and intranasal corticosteroids are the most frequently prescribed symptomatic drugs, but their efficacy is often incomplete. Essential oils (EO) have shown an anti-inflammatory effect and potential in treating patients with AR. The aim of this study was to evaluate the effectiveness of a hypertonic EO-based nasal spray on perennial AR (PAR) symptoms. Methods: This prospective, open-label, non-randomized, multicentric trial included 43 patients with PAR sensitized to mites, not controlled for more than a year. All were treated with Puressentiel® Respiratory-Decongestant Nasal Spray for 30 days. Their usual treatment remained unchanged during the study period. Before and after treatment, each participant filled out a rhinitis questionnaire, the Allergic Rhinitis Control Test (ARCT). A nasal inspiratory peak flow (NIPF) was performed. Results: The mean ARCT was 16.4 and 20.5 at D0 and D30, respectively (p #x3c; 0.001); the mean increase between D0 and D30 was 4.1 (p #x3c; 0.001). The proportion of patients with controlled rhinitis after 30 days of treatment was 69.8 versus 14% before treatment (p #x3c; 0.001). The mean NIPF was 86.5 L/min and 105.1 L/min at D0 and D30, respectively (p #x3c; 0.001); the mean increase between D0 and D30 was 18.5 L/min. Conclusion: A hypertonic EO-based nasal spray could be a new and natural option in the management of PAR. It could also be used as an add-on therapy when nasal symptoms are not fully controlled.
Int Arch Allergy Immunol

更新日期：2020-09-22

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>